Pioglitazone, rosiglitazone, and rosiglitazone + metformin. Glitazone + oral antidiabetic combination: Inadequately evaluated

Prescrire International

Volumn 14, Issue 78, 2005, Pages 133-139

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; GLICLAZIDE; GLIMEPIRIDE; HEMOGLOBIN A1C; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; METFORMIN PLUS ROSIGLITAZONE; MIGLITOL; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE;

ANEMIA; ARTICLE; BLOOD DISEASE; BODY WEIGHT DISORDER; CLINICAL TRIAL; DIABETES CONTROL; DIARRHEA; DISEASE EXACERBATION; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG MARKETING; DRUG SUBSTITUTION; DRUG TOLERABILITY; DYSLIPIDEMIA; EDEMA; FRANCE; HEART FAILURE; HEMODILUTION; HEMOGLOBIN DETERMINATION; HUMAN; HYPOGLYCEMIA; KIDNEY DYSFUNCTION; LEG EDEMA; LIPID BLOOD LEVEL; MONOTHERAPY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRACTICE GUIDELINE; SODIUM RETENTION; WATER RETENTION; WEIGHT GAIN;

CLINICAL TRIALS; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 22144490526     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Prescrire Editorial Staff "Treatment of type 2 diabetes" Prescrire Int 2003; 12 (63): 28-30.
2. Prescrire Editorial Staff "Rosiglitazone and pioglitazone" Prescrire Int 2002; 11 (62): 170-176.
3. GlaxoSmithKline "Clinical trial information for study 49653/145" 22 September 2004. Website http://ctr.gsk.co.uk searched on 5 November 2004.
4. Vongthavaravat V et al. "An international study of the effects of rosiglitazone plus sulphonylurea in patients with type 2 diabetes" Curr Med Res Opin 2002; 18 (8): 456-461.
5. GlaxoSmithKline "Clinical trial information for study 49653/284" 22 September 2004. Website http://ctr.gsk.co.uk searched on 5 November 2004.
6. GlaxoSmithKline "Clinical trial information for study 49653/044" 13 September 2004. Website http://ctr.gsk.co.uk searched on 5 November 2004.
7. Boucher M et al. "Efficy of rosiglitazone and pioglitazone compared to other anti-diabetic agents: systematic review and budget impact analysis" Canadian co-ordinating office for health technology assessment, Ottawa, October 2002. Technology Report no29. Website http://www.ccohta.ca searched on 4 November 2004.
8. Barnett AH et al. "Rosiglitazone in type 2 diabetes mellitus: an evaluation in British Indo-Asian patients" Diabet Med 2003; 20: 387-393.
9. GlaxoSmithKline "Clinical trial information for study 49653/162" 27 August 2004. Website http://ctr.gsk.co.uk searched on 5 November 2004.
10. GlaxoSmithKline "Clinical trial information for study 49653/135" 27 August 2004. Website http://ctr.gsk.co.uk consulted on 5 November 2004.
11. GlaxoSmithKline "Clinical trial information for study 49653/234" 27 August 2004. Website http://ctr.gsk.co.uk searched on 5 November 2004.
12. GlaxoSmithKline "Clinical trial information for study 49653/143" 27 August 2004. Website http://ctr.gsk.co.uk searched on 5 November 2004.
13. GlaxoSmithKline "Clinical trial information for study 49653/127" 22 Sept 2004. Website http://ctr.gsk.co.uk searched on 5 November 2004.
14. National Institute for Clinical Excellence "The clinical effectiveness and cost effectiveness of rosiglitazone for type 2 diabetes mellitus" May 2000. Website http://www.nice.org.uk searched on 2 October 2003.
15. Yang J et al. "Effect of addition of low-dose rosiglitazone to sulphonylurea therapy on glycemic control in type 2 diabetic patients" Chin Med J 2003; 116 (5): 785-787.
16. Garber AJ et al. "Glyburide*/metformin tablets versus metformin plus rosiglitazone in type 2 diabetes patients uncontrolled on metformin: attaining glycemic goals" American Diabetes Association 63rd scientific sessions, New Orleans June 2003 (abstr. 513): 1 page.
17. Derosa G et al. "Actions of glimepiride plus metformin compared to rosiglitazone plus metformin on glucose metabolism fibrinolytic, and coagulation measurements in type 2 diabetic patients" 18th congress of the International Diabetes Federation, Paris August 2003 (abstr. 2282): 1 page.
18. Hanefeld M et al. "One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes" Diabetes Care 2004: 27 (1): 141-147.
19. Mariz S et al. "Safety and tolerability of pioglitazone compared to metformin and gliclazide in type 2 diabetes - results from active comparator trials" 18th congress of the International Diabetes Federation, Paris August 2003 (abstr. 2290): 3 pages.
20. French pharmacoeconomic Committee "Avis de la Commission - Actos" 24 March 2004: 15 pages.
21. Nagasaka S et al. "Comparison of pioglitazone and metformin efficacy using homeostasis model assessment" Diabet Med 2004; 21: 136-141.
22. Umpierrez G et al. "The role of glimepiride (GLIM) vs pioglitazone (PIO) in type 2 diabetes mellitus subjects not responding adequately to metformin (MET) monotherapy" American Diabetes Association 64th scientific sessions, Orlando June 2004 (abstr. 627-P): 1 page.
23. Moules I et al. "Two-year efficacy of the addition of pioglitazone to sulfonylurea therapy in patients with T2DM" American Diabetes Association 64th scientific sessions, Orlando June 2004 (abstr. 584-P): 1 page.
24. Raz I et al. "In inadequately controlled patients with type 2 diabetes, biphasic insulin aspart 30 combined with pioglitazone provides better glycemic control than biphasic insulin aspart 30 monotherapy or pioglitazone/sulfonylurea combination" American Diabetes Association 63rd scientific sessions, New Orleans June 2003 (abstr. 1064): 1 page.
25. Derosa G et al. "Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial" Clin Ther 2004; 26 (5): 744-754.
26. o. En monothérapie de deuxième ligne: une nouvelle indication non justifiée par l'évaluation clinique" Rev Prescrire 2005: 25 (259): 175-179.
27. Eckland D et al. "Cardiac safety of pioglitazone in comparison with metformin and gliclazide" 18th congress of the International Diabetes Federation, Paris August 2003 (abstr. 841): 3 pages.
28. Delea TE et al. "Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes" Diabetes Care 2003; 26 (11): 2983-2989.
29. Nesto RW et al. "Thiazolidinedione use, fluid retention, and congestive heart failure. A consensus statement from the American Heart Association and American Diabetes Association" Diabetes Care 2004; 27 (1): 256-263.
30. o - Summary of Product Characteristics" July 2004: 22 pages.
31. o". In French datasheet compendium: "Dictionnaire Vidal", Vidal, Issy-les-Moulineaux 2005: 20-21.
32. o". In French datasheet compendium: "Dictionnaire Vidal", Vidal, Issy-les-Moulineaux 2005: 184-185.
33. Lambert C et al. "Weight changes with treatment of type 2 diabetes with pioglitazone, metformin and gliclazide" 18th congress of the international Diabetes Federation, Paris August 2003 (abstr. 1885): 3 pages.
34. The European Agency for the Evaluation of Medicinal Products - Committee for Proprietary Medicinal Products "European Public Assessment Report (EPAR) - Avandamet: Scientific discussion" 2003: 18 pages.
35. Kinley J et al. "Changes in haematological variables with one-year treatment with pioglitazone, metformin and gliclazide in 3 713 - type 2 - diabetic patients" 18th Congress of the International Diabetes Federation, Paris August 2003 (abstr. 2291): 3 pages.
36. GlaxoSmithKline "GlaxoSmithKline announces RECORD. A benchmark study to determine effects of reducing insulin resistance on cardiovascular risk" Undated press release, received on 20 March 2002: 3 pages.
37. Jovanovic L et al. "Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone" Diabetes Res Clin Pract 2004; 63 (2): 127-134.
38. Raskin P et al. "Combination therapy for Type 2 diabetes: repaglinide plus rosiglitazone" Diabet Med 2004; 21: 329-335.
39. Rosak C et al. "Rosiglitazone is effective and safe in daily practice" 18th Congress of the International Diabetes Federation, Paris August 2003 (abstr. 842): 1 page.